Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial

Jonas Holm, Gabriele Ferrari, Anders Holmgren, Farkas Vanky, Örjan Friberg, Mårten Vidlund, Rolf Svedjeholm, Jonas Holm, Gabriele Ferrari, Anders Holmgren, Farkas Vanky, Örjan Friberg, Mårten Vidlund, Rolf Svedjeholm

Abstract

Background: Animal and human data suggest that glutamate can enhance recovery of myocardial metabolism and function after ischemia. N-terminal pro-brain natriuretic peptide (NT-proBNP) reflects myocardial dysfunction after coronary artery bypass surgery (CABG). We investigated whether glutamate infusion can reduce rises of NT-proBNP in moderate- to high-risk patients after CABG.

Methods and findings: A prospective, randomized, double-blind study enrolled patients from November 15, 2015 to September 30, 2020, with a 30-day follow-up at 4 academic cardiac surgery centers in Sweden. Patients underwent CABG ± valve procedure and had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h started 10 to 20 minutes before releasing the aortic cross-clamp, then continued for another 150 minutes. Patients, staff, and investigators were blinded to the treatment. The primary endpoint was the difference between preoperative and day-3 postoperative NT-proBNP levels. Analysis was intention to treat. We studied 303 patients (age 74 ± 7 years; females 26%, diabetes 47%), 148 receiving glutamate group and 155 controls. There was no significant difference in the primary endpoint associated with glutamate administration (5,390 ± 5,396 ng/L versus 6,452 ± 5,215 ng/L; p = 0.086). One patient died ≤30 days in the glutamate group compared to 6 controls (0.7% versus 3.9%; p = 0.12). No adverse events linked to glutamate were observed. A significant interaction between glutamate and diabetes was found (p = 0.03). Among patients without diabetes the primary endpoint (mean 4,503 ± 4,846 ng/L versus 6,824 ± 5,671 ng/L; p = 0.007), and the incidence of acute kidney injury (11% versus 29%; p = 0.005) was reduced in the glutamate group. These associations remained significant after adjusting for differences in baseline data. The main limitations of the study are: (i) it relies on a surrogate marker for heart failure; and (ii) the proportion of patients with diabetes had almost doubled compared to the cohort used for the sample size estimation.

Conclusions: Infusion of glutamate did not significantly reduce postoperative rises of NT-proBNP. Diverging results in patients with and without diabetes agree with previous observations and suggest that the concept of enhancing postischemic myocardial recovery with glutamate merits further evaluation.

Trial registration: ClinicalTrials.gov https://ichgcp.net/clinical-trials-registry/NCT02592824. European Union Drug Regulating Authorities Clinical Trials Database (Eudra CT number 2011-006241-15).

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Doenst T, Amorim PA. Metabolic therapy in cardiac surgery–“Optimizing the engine’s fuel supply and more…”. Scand Cardiovasc J. 2010;44:4–8. doi: 10.3109/14017430903469928
    1. Rau EE, Shine KI, Gervais A, Douglas AM, Amos EC. Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion. Am J Physiol. 1979;236:H873–H9. doi: 10.1152/ajpheart.1979.236.6.H873
    1. Pisarenko OI. Mechanisms of myocardial protection by amino acids: facts and hypotheses. Clin Exp Pharmacol Physiol. 1996;23:627–33. doi: 10.1111/j.1440-1681.1996.tb01748.x
    1. Burns AH, Reddy WJ. Amino acid stimulation of oxygen and substrate utilization by cardiac myocytes. Am J Physiol Endocrinol Metab. 1978;235:E461. doi: 10.1152/ajpendo.1978.235.5.E461
    1. Pisarenko OI, Oleynikov OD, Shulzhenko VS, Studneva IM, Ryff IM, Kapelko VI. Association of myocardial glutamate and aspartate pool and functional recovery of postischemic heart. Biochem Med Metab Biol. 1989;42:105–17. doi: 10.1016/0885-4505(89)90046-7
    1. Lazar HL, Buckberg GD, Manganaro AM, Becker H. Myocardial energy replenishment and reversal of ischemic damage by substrate enhancement of secondary blood cardioplegia with amino acids during reperfusion. J Thorac Cardiovasc Surg. 1980;80:350–9.
    1. Mudge GH Jr, Mills RM Jr, Taegtmeyer H, Gorlin R, Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Invest. 1976;58:1185–92. doi: 10.1172/JCI108571
    1. Thomassen AR, Nielsen TT, Bagger JP, Henningsen P. Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease. Clin Sci (Lond). 1983;64:33–40. doi: 10.1042/cs0640033
    1. Svedjeholm R, Ekroth R, Joachimsson PO, Ronquist G, Svensson S, Tydén H. Myocardial uptake of amino acids and other substrates in relation to myocardial oxygen consumption four hours after cardiac operations. J Thorac Cardiovasc Surg. 1991;101:688–94.
    1. Kimose HH, Ravkilde J, Helligsö P, Knudsen MA, Thomassen AR, Nielsen TT, et al.. Myocardial loss of glutamate after cold chemical cardioplegia and storage in isolated blood-perfused pig hearts. Thorac Cardiovasc Surg. 1993;41:93–100. doi: 10.1055/s-2007-1013829
    1. Pisarenko OI, Lepilin MG, Ivanov VE. Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure. Clin Sci (Lond). 1986;70:7–12. doi: 10.1042/cs0700007
    1. Svedjeholm R, Vanhanen I, Hakanson E, Joachimsson PO, Jorfeldt L, Nilsson L. Metabolic and hemodynamic effects of intravenous glutamate infusion early after coronary operations. J Thorac Cardiovasc Surg. 1996;112:1468–77. doi: 10.1016/S0022-5223(96)70005-3
    1. Svedjeholm R, Vidlund M, Vanhanen I, Hakanson E. A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG. Scand Cardiovasc J. 2010;44:45–58. doi: 10.3109/14017430903531008
    1. Vidlund M, Hakanson E, Friberg O, Juhl-Andersen S, Holm J, Vanky F, et al.. GLUTAMICS—a randomized clinical trial on glutamate infusion in 861 patients undergoing surgery for acute coronary syndrome. J Thorac Cardiovasc Surg. 2012;144(922–30):e7. doi: 10.1016/j.jtcvs.2012.05.066
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al.. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628–51. doi: 10.1016/j.cardfail.2017.04.014
    1. Fox AA, Shernan SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, et al.. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008;136:452–61. doi: 10.1016/j.jtcvs.2007.12.036
    1. Nozohoor S, Nilsson J, Luhrs C, Roijer A, Algotsson L, Sjogren J. B-type natriuretic peptide as a predictor of postoperative heart failure after aortic valve replacement. J Cardiothorac Vasc Anesth. 2009;23:161–5. doi: 10.1053/j.jvca.2008.11.006
    1. Suttner S, Boldt J, Lang K, Rohm KD, Piper SN, Mayer J. Association of N-terminal pro-brain natriuretic peptide and cardiac troponin T with in-hospital cardiac events in elderly patients undergoing coronary artery surgery. Eur J Anaesthesiol. 2008;25:834–41. doi: 10.1017/S0265021508004365
    1. Kerbaul F, Collart F, Giorgi R, Oddoze C, Lejeune PJ, Guidon C, et al.. Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery. Intensive Care Med. 2004;30:1799–806. doi: 10.1007/s00134-004-2299-0
    1. Provenchere S, Berroeta C, Reynaud C, Baron G, Poirier I, Desmonts JM, et al.. Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with postoperative cardiac dysfunction and 1-year mortality. Crit Care Med. 2006;34:995–1000. doi: 10.1097/01.CCM.0000206110.94385.C4
    1. Jiang H, Vánky F, Hultkvist H, Holm J, Yang Y, Svedjeholm R. NT-proBNP and postoperative heart failure in surgery for aortic stenosis. Open Heart. 2019;6:e001063. doi: 10.1136/openhrt-2019-001063
    1. O’Connor GT, Birkmeyer JD, Dacey LJ, Quinton HB, Marrin CA, Birkmeyer NJ, et al.. Results of a regional study of modes of death associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 1998;66:1323–8. doi: 10.1016/s0003-4975(98)00762-0
    1. Surgenor SD, O’Connor GT, Lahey SJ, Quinn R, Charlesworth DC, Dacey LJ, et al.. Predicting the risk of death from heart failure after coronary artery bypass graft surgery. Anesth Analg. 2001;92:596–601. doi: 10.1097/00000539-200103000-00008
    1. Vanky F, Hakanson E, Maros T, Svedjeholm R. Different characteristics of postoperative heart failure after surgery for aortic stenosis and coronary disease. Scand Cardiovasc J. 2004;38:152–8. doi: 10.1080/14017430410029734
    1. Lazar HL, Buckberg GD, Foglia RP, Manganaro AJ, Maloney JV Jr. Detrimental effects of premature use of inotropic drugs to discontinue cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1981;82:18–25.
    1. Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108:979–87. doi: 10.1097/ALN.0b013e318173026f
    1. Jiang H, Holm J, Vidlund M, Vanky F, Friberg Ö, Yang Y, et al.. The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study. J Transl Med. 2020;18:193. doi: 10.1186/s12967-020-02351-7
    1. Jiang H, Hultkvist H, Holm J, Vanky F, Yang Y, Svedjeholm R. Impact of underlying heart disease per se on the utility of preoperative NT-proBNP in adult cardiac surgery. PLoS ONE. 2018;13:e0192503. doi: 10.1371/journal.pone.0192503
    1. Jiang H, Holm J, Friberg O, Vanky F, Vidlund M, Tajik B, et al.. Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study. Perioper Med (Lond). 2021;10:21. doi: 10.1186/s13741-021-00194-4
    1. Sutherland L, Hittesdorf E, Yoh N, Lai T, Mechling A, Wagener G. Acute kidney injury after cardiac surgery: A comparison of different definitions. Nephrology (Carlton). 2020;25:212–8. doi: 10.1111/nep.13669
    1. Priyanka P, Zarbock A, Izawa J, Gleason TG, Renfurm RW, Kellum JA. The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients. J Thorac Cardiovasc Surg. 2021;162(143–51):e7. doi: 10.1016/j.jtcvs.2019.11.137
    1. Lassnigg A, Schmid ER, Hiesmayr M, Falk C, Druml W, Bauer P, et al.. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med. 2008;36:1129–37. doi: 10.1097/CCM.0b013e318169181a
    1. Langenberg CJ, Pietersen HG, Geskes G, Wagenmakers AJ, Lange SD, Schouten HJ, et al.. The effect of glutamate infusion on cardiac performance is independent of changes in metabolism in patients undergoing routine coronary artery bypass surgery. Clin Sci (Lond). 2001;101:573–80.
    1. Vanhanen I, Svedjeholm R, Håkanson E, Joachimsson PO, Jorfeldt L, Nilsson L, et al.. Assessment of myocardial glutamate requirements early after coronary artery bypass surgery. Scand Cardiovasc J. 1998;32:145–52. doi: 10.1080/14017439850140102
    1. Povlsen JA, Lofgren B, Rasmussen LE, Nielsen JM, Norregaard R, Kristiansen SB, et al.. Cardioprotective effect of L-glutamate in obese type 2 diabetic Zucker fatty rats. Clin Exp Pharmacol Physiol. 2009;36:892–8. doi: 10.1111/j.1440-1681.2009.05166.x
    1. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009;54:1891–8. doi: 10.1016/j.jacc.2009.07.031
    1. Fox AA, Muehlschlegel JD, Body SC, Shernan SK, Liu KY, Perry TE, et al.. Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting. Anesthesiology. 2010;112:842–51. doi: 10.1097/ALN.0b013e3181d23168

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren